Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Vaxart  (Stock symbol: VXRT )

290 Utah Avenue
South San Francisco, CA 94080
USA
650 550 3500
Website Company Summary Management Team
Management

General Management: James Cummings (9/27/2021)
Finance: John Harland (5/8/2014)
Technology: Sean Tucker
General Counsel/Legal: Edward Berg
Board

Outside board: (May no longer be on the board) Richard J Markham (Capital Care) Michael Finney (Vaxart) Jan Leschly (Care Capital)
Company

Business description: Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. We believe the Vaxart platform is suitable to deliver many recombinant protein antigens such as those used in currently marketed influenza, hepatitis B and human papilloma virus (HPV) vaccines, as well as many other recombinant vaccines currently in the industry pipeline. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. All intellectual property is fully owned by Vaxart, without any encumbrances. With modular creation using standard recombinant techniques, we believe we can create new vaccines very quickly to protect against emerging pathogens such as avian influenza or biodefense threats.
Capital

Rounds: 3
Recent Fundings: Aug 2013   Jun 2012
Capital raised: 52.7M
Last Round: 20.0M
Ownership: Public   Ipo Filing
Stock Symbol: VXRT
VCs include: Bay PartnersCare Capital ;  Quantum Technology Partners;  Xandex Investments

Last Tweets


 

Last Mentions


Overview
Record updated: Feb 2022
Sector: Biotech
Year Founded: 2004
Headcount: 101-150 as of Feb 2022
Rounds: 3
Recent Fundings: Aug 2013   Jun 2012
Capital Raised: 52.7M
Last Round: 20.0M
Ownership: Public   Ipo Filing
Stock Symbol: VXRT